Company intelligence / Profile preview

RIS Rx

Newport Beach, California, United States

Ownership: Private
Development stage: Other

Overview

RIS Rx delivers proprietary software and pharmacist-led expertise that have driven over $450 million in gross-to-net savings in 2024 and is projected to surpass $1 billion in 2025 for pharmaceutical manufacturer partners, focusing on real-time revenue leakage prevention and patient affordability program efficiency.

Industry: Biomedical IT and Biomedical Data Platforms

Beyond the preview

Go deeper on RIS Rx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIS Rx.

Explore the full profile